Hackensack Meridian Health and Neosoma, Inc., an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers through the use of artificial intelligence (AI), announce a new strategic partnership to tackle some of the most difficult-to-treat tumors.
The collaboration will include clinical data sharing, clinical research, and strategic investment from the health network to support the Massachusetts-based company’s innovative method of imaging, tracking and collecting data on numerous types of brain tumors including glioblastomas.
“We are committed to investing in research and innovative therapies to live our mission to transform healthcare and give our patients the best possible outcomes,” said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health. “Partnering with Neosoma Inc. is a great way to continue to develop potential game changing therapies to treat these challenging cancers.”
“We have a terrific partnership with Hackensack Meridian Health already,” said Ken Kolodziej, the CEO and co-founder of Neosoma. “We’re very excited to expand the scope of our collaboration with the shared goal of improving treatment and outcomes for patients with brain cancer.”
Also Read: McAfee Report Details How Advancement in AI is Creating New Mobile Threats, Aiding Scammers
The partnership will include HMH physicians using Neosoma’s software in clinical practice, starting with Hackensack Meridian JFK University Medical Center; physician input and feedback for development of future software including neurosurgeons, neuro-oncologists, neuroradiologists, radiation oncologists, and other clinicians; and data sharing for product R&D efforts including collaboration with Anthology Diagnostics for genomics data and capabilities, among other benefits.
Neosoma recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for its first AI-based neuro-oncology software device, Neosoma HGG (High-Grade Glioma). The technology produces precise and accurate brain tumor analysis on MRIs, providing physicians with critical insights to guide treatment decisions.
In clinical practice, the brain MRI is the physician’s best tool to evaluate the details and changes in a brain tumor. But even the most experienced physicians encounter considerable challenges in determining the extent and characteristics of the cancer, which can have a direct impact on clinical care.
The Neosoma technology will help physicians to better plan procedures, assess post-procedural results, guide chemo and immunotherapy treatments, track patients longitudinally, support an improved patient experience, and help lead to improved treatment, according to the company.
SOURCE: PR Newswire